Skip to main content
SpringerLink
Log in

Antiglutamate therapy of ALS — which is the next step?

  • Conference paper
Advances in Research on Neurodegeneration

Part of the book series: 6th International Winter Conference on N eurodegeneration ((NEURAL SUPPL,volume 55))

  • 75 Accesses

Summary

Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease which was thought to be untreatable for a long time. However, recent evidence in men indicates that antiglutamatergic strategies are the first to have an influence on its pathogenesis and slow down the disease process. Since the effect of the drugs is still small, this progress cannot only be seen as a success of the present but most also be acknowledged as a starting point for the future. How will these future studies look like? They will have to take into account that ALS presumably has a long preclinical period and they will use a number of novel compounds and treatment strategies which have recently been shown to be effective in a transgenic animal model. This also implies that we are likely to use combination therapies and have to try to treat patients early. The latter will be necessarily connected with the demand for a novel clinical attitude to the diagnosis of the disease.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 39.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 54.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  • Ankercrona M, Dypbukt JM, Bonfoco E, Zhivotovsky B, Orrenius S, Lipton SA, Nicotera P (1995) Apoptosis and mitochondria. Neuron 15: 961–973.

    Article  Google Scholar 

  • Aoki M, Lin CL, Rothstein JD, Geller BA, Hosier BA, Munsat TL, Horvitz HR, Brown RH Jr (1998) Mutations in the glutamate transporter EAAT2 gene do not cause abnormal EAAT2 transcripts in amyotrophic lateral sclerosis. Ann Neurol 43: 645–653.

    Article  PubMed  CAS  Google Scholar 

  • Azzouz M, Leclerc N, Gurney M, Warter JM, Poindron P, Borg J (1997) Progressive motor neuron impairment in an animal model of familial amyotrophic lateral sclerosis. Muscle Nerve 20: 45–51.

    Article  PubMed  CAS  Google Scholar 

  • Beal MF (1992) Does impairment of energy metabolism result in excitotoxic neuronal death in neurodegenerative illnesses? Ann Neurol 31: 119–130.

    Article  PubMed  CAS  Google Scholar 

  • Benazzouz A, Boraud T, Dubédat P, Boireau A, Stutzmann JM, Gross C (1995) Riluzole prevents MPTP-induced parkinsonism in the rhesus monkey: a pilot study. Eur J Pharmacol 284: 299–307.

    Article  PubMed  CAS  Google Scholar 

  • Benoit E, Escande D (1991) Riluzole specifically blocks inactivated Na+ channels in myelinated nerve fibers. Pflügers Arch 419: 603–609.

    Article  PubMed  CAS  Google Scholar 

  • Bensimon G, Lacomblez L, Meininger V and the ALS/Riluzole Study Group (1994) A controlled trial of riluzole in amyotrophic lateral sclerosis. N Engl J Med 330: 585–591.

    Article  PubMed  CAS  Google Scholar 

  • Block W, Karitzky J, Traber F, Pohl C, Keller E, Mundegar RR, Lamerichs R, Rink H, Ries F, Schild HH, Jerusalem F (1998) Proton magnetic resonance spectroscopy of the primary motor cortex in patients with motor neuron disease. Sub-group analysis and follow-up measurements. Arch Neurol 55: 931–936.

    Article  PubMed  CAS  Google Scholar 

  • Boireau A, Dubédat P, Bordier F, Peny C, Miquet JM, Durand G, Meunier M, Doble A (1994) Riluzole and experimental parkinsonism: antagonism of MPTP-induced decrease in central dopamine levels in mice. Neuroreport 5: 2657–2660.

    Article  PubMed  CAS  Google Scholar 

  • Bruijn LI, Becher MW, Lee MK, Anderson KL, Jenkins NA, Copeland NG, Sisodia SS, Rothstein JD, Borchelt DR, Price DL, Cleveland DW (1997) ALS-linked SOD1 mutant G85R mediates damage to astrocytes and promotes rapidly progressive disease with SOD1-containing inclusions. Neuron 18: 327–338.

    Article  PubMed  CAS  Google Scholar 

  • Burright EN, Clark HB, Servadlo A, Matilla T, Feddersen RM, Yunis WS, Duvick LA, Zoghbi HY, Orr HAT (1995) SCA1 transgenic mice: a model for neurodegeneration caused by an expanded CAG trinucleotide repeat. Cell 82: 937–948.

    Article  PubMed  CAS  Google Scholar 

  • Charcot JM (1974) Lecons sur les maladies du systéme nerveux faites à la Salpetrière. Paris. Progrès Medical 213-242.

    Google Scholar 

  • Cheramy A, Barbeito L, Godeheu G, Glowinsky J (1992) Riluzole inhibits the release of glutamate in the caudate nucleus of the cat in vivo. Neurosci Lett 147: 209–212.

    Article  PubMed  CAS  Google Scholar 

  • Chiu AY, Zhai P, Dal Canto MC, Peters TM, Kwon YW, Prattis TM, Gurney ME (1995) Age-dependent penetrance of disease in a transgenic mouse model of familial amyotrophic lateral sclerosis. Mol Cell Neurosci 6: 349–362.

    Article  PubMed  CAS  Google Scholar 

  • Choi DW (1998) Glutamate neurotoxicity and diseases of the nervous system. Neuron 1: 623–634.

    Article  Google Scholar 

  • Couratier P, Hugon J, Sindou P, Vallat JM, Dumas M (1993) Cell culture evidence for neuronal degeneration in amyotrophic lateral sclerosis being linked to glutamate AMPA/kainate receptors. Lancet 341: 265–268.

    Article  PubMed  CAS  Google Scholar 

  • Couratier P, Sindou P, Esclaire F, Louvel E, Hugon J (1994) Neuroprotective effects of riluzole in ALS CSF toxicity. Neuroreport 5: 1012–1014.

    Article  PubMed  CAS  Google Scholar 

  • Dal Canto MC, Gurney ME (1994) Development of central nervous system pathology in a murine transgenic model of human amyotrophic lateral sclerosis. Am J Pathol 145: 1271–1279.

    Google Scholar 

  • Doble A (1996) The pharmacology and mechanism of action of riluzole. Neurology 47 [Suppl 4]: 233–241.

    Google Scholar 

  • Doble A (1997) Effects of riluzole on glutamatergic neurotransmission in the mammalian central nervous system, and other pharmacological effects. Rev Contemp Pharmacother 8: 213–225.

    CAS  Google Scholar 

  • Dugan LL, Turetsky DM, Du C, Lobner D, Wheeler M, Almli CR, Shen CK, Luh TY, Choi DW (1997) Carboxyfullerenes as neuroprotective agents. Proc Natl Acad Sci USA 94: 9434–9439.

    Article  PubMed  CAS  Google Scholar 

  • Friedländer RM, Brown RH, Gagliardini V, Wang J, Yuan J (1997) Inhibition of ICE slows ALS in mice. Science 388: 31.

    Google Scholar 

  • Gravel C, Götz R, Lorrain A, Sendtner M (1997) Adenoviral gene transfer of ciliary neurotrophic factor and brain-derived neurotrophic factor leads to long-term survival of axotomized motor neurons. Nat Med 3: 765–770.

    Article  PubMed  CAS  Google Scholar 

  • Gurney M, Pu H, Chiu A, Dal Canto M, Polchow C, Alexander D, Caliendo J, Hantati A, Kwon Y, Deng H, Chen W, Zhai P, Sifit R, Siddique T (1994) Motor neuron degeneration in mice that express a human Cu, Zn Superoxide dismutase mutation. Science 264: 1773–1775.

    Article  Google Scholar 

  • Gurney M, Cutting FB, Zhai P, Doble A, Taylor C, Andrus PK, Hall ED (1996) Benefit of vitamin E, riluzole, and gabapentin in a transgenic model of familial amyotrophic lateral sclerosis. Ann Neurol 39: 147–157.

    Article  PubMed  CAS  Google Scholar 

  • Guyot MC, Palfi S, Stutzmann JM, Maziere M, Hantraye P, Brouillet E (1997) Riluzole protects from motor deficits and striatal degeneration produced by systemic 3-nitropropionic acid intoxication in rats. Neuroscience 81: 141–149.

    Article  PubMed  CAS  Google Scholar 

  • Haase G, Kennel P, Pettmann B, Vigne E, Akli S, Revah F, Schmalbruch H, Kahn A (1997) Gene therapy of murine motor neuron disease using adenoviral vectors for neurotrophic factors. Nat Med 3: 429–436.

    Article  PubMed  CAS  Google Scholar 

  • Hengartner MO (1998) Death cycle and Swiss army knives. Nature 391: 441–442.

    Article  PubMed  CAS  Google Scholar 

  • Henneberry RC, Novelli A, Cox JA, Lysko PG (1989) Neurotoxicity at the N-methyl-D-aspartate receptor in energy-compromised neurons: an hypothesis for cell death in aging and disease. Ann NY Acad Sci 568: 225–233.

    Article  PubMed  CAS  Google Scholar 

  • Hottinger AF, Fine EG, Gurney ME, Zum AD, Aebischer P (1997). The copper chelator d-penicillamine delays onset of disease and extends survival in a transgenic mouse model of familial amyotrophic lateral sclerosis. Eur J Neurosci 9: 1548–1551.

    Article  PubMed  CAS  Google Scholar 

  • Hubert JP, Delumeau JC, Prémont J, Glowinski J, Doble A (1994) Antagonism by riluzole of entry of calcium evoked by NMDA and veratridine in rat cultured granule cells: evidence for a dual mecahnism of action. Br J Pharmacol 113: 261–267.

    PubMed  CAS  Google Scholar 

  • Ikonomidou C, Qin YQ, Labruyere J, Olney JW (1996) Motor neuron degeneration induced by excitotoxin agonists has features in common with those seen in the SOD-1 transgenic mouse model of amyotrophic lateral sclerosis. J Neuropathol Exp Neurol 55: 211–224.

    Article  PubMed  CAS  Google Scholar 

  • Jain RK (1998) The next frontier of molecular medicine: Delivery of therapeutics. Nature Med 4: 655–657.

    Article  PubMed  CAS  Google Scholar 

  • Kong J, Xu Z (1998) Massive mitochondrial degeneration in motor neurons triggers the onset of amyotrophic lateral sclerosis in mice expressing a mutant SOD1. J Neurosci 18: 3241–3250.

    PubMed  CAS  Google Scholar 

  • Kostic V, Jackson-Lewis V, de Bilbao F, Dubois-Dauphin M, Przedborski S (1997) Bcl-2: prolonging life in a transgenic mouse model of familial amyotrophic lateral sclerosis. Science 277: 559–562.

    Article  PubMed  CAS  Google Scholar 

  • Lacomblez L, Bensimon G, Leigh PN, Guillet P, Meininger V (1996) Dose-ranging study of riluzole in amyotrophic lateral sclerosis. Lancet 347: 1425–1431.

    PubMed  CAS  Google Scholar 

  • Leist M, Nicotera P (1998) Apotosis, excitoxicity, and neuropathology. Exp Cell Res 239: 183–201.

    Article  PubMed  CAS  Google Scholar 

  • Lin CLG, Bristol LA, Jin L, Dykes-Hoberg M, Crawford T, Clawson L, Rothstein JD (1998) Aberrant RNA processing in a neurodegenerative disease: the cause for absent EAAT2, a glutamate transporter, in amyotrophic lateral sclerosis. Neuron 20: 589–602.

    Article  PubMed  CAS  Google Scholar 

  • Löscher W, Hönack D, Taylor CP (1991) Gabapentin increases aminooxyacetic acidinduced GABA accumulation in regions of rat brain. Neurosci Lett 128: 150–154.

    Article  PubMed  Google Scholar 

  • Louvel E, Hugon J, Doble A (1997) Therapeutic advances in amyotrophic lateral sclerosis. TIPS 18: 196–203.

    PubMed  CAS  Google Scholar 

  • Lucas DR, Newhouse JP (1957) The toxic effect of sodium L-glutamate on the inner layers of the retina. Arch Ophtalmol 58: 193–204.

    Article  CAS  Google Scholar 

  • 5Ludolph AC, Riepe MW (1999) Do the benefits of currently available treatments justify early diagnosis and treatment of amyotrophic laterals sclerosis? Against, in press.

    Google Scholar 

  • Ludolph AC, Riepe M, Ullrich K (1993) Excitotoxicity, energy metabolism and neuronal degeneration. J Inher Metab Dis 16: 716–723.

    Article  PubMed  CAS  Google Scholar 

  • Malessa S, Leigh PN, Bertel O, Sluga E, Hornykiewicz O (1991) Amyotrophic lateral sclerosis: glutamate dehydrogenase and transmitter amino acids in the spinal cord. J Neurol Neurosurg Psychiatry 54: 984–988.

    Article  PubMed  CAS  Google Scholar 

  • Malgouris C, Bardot F, Daniel M, Pellis F, Rataud J, Uzan A, Blanchard C, Laduron RM (1989) Riluzole, a novel antiglutamate, prevents memory loss and hippocampal neuronal damage in ischémic gerbils. J Neurosci 9: 3720–3727.

    PubMed  CAS  Google Scholar 

  • Martin D, Thompson MA, Nadler JV (1993) The neuroprotective agent riluzole inhibits release of glutamate and asparatate from slices of hippocampal area CA1. Eur J Pharmacol 250: 473–476.

    Article  PubMed  CAS  Google Scholar 

  • Masliah E, Alford M, DeTeresa R, Mallory M, Hansen L (1996) Deficient glutamate transport is associated with neurodegeneration in Alzheimer’s disease. Ann Neurol 40: 759–766.

    Article  PubMed  CAS  Google Scholar 

  • Masliah E, Raber J, Alford M, Mallory M, Mattson MP, Yang D, Wong D, Mucke L (1998) Amyloid protein precursor stimulates excitatory amino acid transport. Implications for roles in neuroprotection and pathogenesis. J Biol Chem 273:12548–12554.

    Article  PubMed  CAS  Google Scholar 

  • Meyer T, Lenk U, Küther GL, Speer A, Weindl A, Ludolph AC (1995) Studies of the coding region of the neuronal glutamate transporter (EAAC1) gene in ALS. Ann Neurol 37: 817–819.

    Article  PubMed  CAS  Google Scholar 

  • Meyer T, Meyer B, Münch C, Sitte W, Küther G, Speer A, Ludolph AC (1996) The glial glutamate transporter cDNA in patients with amyotrophic lateral sclerosis. Ann Neurol 40: 456–459.

    Article  PubMed  CAS  Google Scholar 

  • Meyer T, Ludolph AC, Morkel M, Hagemeier C, Speer A (1997) Genomic organization of the human excitatory amino acid transporter gene GLT-1. Neuroreport 8: 775–777.

    Article  PubMed  CAS  Google Scholar 

  • Meyer T, Münch C, Knappenberger B, Liebau S, Völkel H, Ludolph AC (1998a) Alternative splicing of the glutamate transporter EAAT2. Neurosci Lett 241: 1–3.

    Article  Google Scholar 

  • Meyer T, Münch C, Völkel H, Booms P, Ludolph AC (1998b) The EAAT 2 (GLT-1) gene in motor neuron disease: Absence of mutations in amyotrophic lateral sclerosis and a point mutation in individuals with hereditary spastic paraplegia. J Neurol Neurosurg Psychiatry, in press.

    Google Scholar 

  • Miller RG, Moore D, Young LA, Armon C, Barohn RJ, Bromberg MB, Bryan WW, Gelinas DF, Mendoza MC, Neville HE, Parry GJ, Petajan JH, Ravits JM, Ringel SP, Ross MA, the WALS Study Group (1996) Placebo-controlled trial of gabapentin in patients with amyotrophic lateral sclerosis. Neurology 47: 1383–1388.

    PubMed  CAS  Google Scholar 

  • Mizoule J, Meldrum D, Mazadier M, Croucher M, Ollat C, Uzan A, Legrand J, Gueremy C, Le Fur G (1985) 2-amino-6-trifluoromethoxybenzothiazole, a possible antagonist of excitatory amino acid transmission. 1. Anticonvulsant properties. Neuropharmacol 24: 767–773.

    Article  CAS  Google Scholar 

  • Münch C, Schwalenstöcker B, Liebau S, Völkel H, Ludolph AC, Meyer T (1998) 5′-Heterogeneity of the human glutamate transporter cDNA EAAT2 (GLT-1). Neuroreport 9: 1295–1297.

    Article  PubMed  Google Scholar 

  • Nagai M, Abe K, Okamoto K, Itoyama Y (1998) Identification of alternative splicing forms of GLT-1 mRNA in the spinal cord of amyotrophic lateral sclerosis patients. Neurosci Lett 244: 165–168.

    Article  PubMed  CAS  Google Scholar 

  • Ochs G, Penn RD, Beck M, Giess R, Magnus T, Sims T, Sendtner M, Toyka KV (1998) Intrathecal infusion of recombinant human-brain-derived neurotrophic factor (rhBDNF) is well tolerated in patients with ALS. Abstract, 9th International Symposium on ALS/MND.

    Google Scholar 

  • Olney JW (1969a) Brain lesions, obesity, and other disturbances in mice treated with monosodium glutamate. Science 164: 719–721.

    Article  PubMed  CAS  Google Scholar 

  • Olney JW (1969b) Glutamate-induced retinal degeneration in neonatal mice. Electron microscopy of the acutely evolving lesion. J Neuropathol Exp Neurol 28: 455–474.

    Article  PubMed  CAS  Google Scholar 

  • Parkes TL, Elia AJ, Dickinson D, Hilliker AJ, Phillips JP, Boulianne GL (1998) Extension of Drosophila lifespan by overexpression of human SOD1 in motorneurons. Nat Gen 19: 171–174.

    Article  CAS  Google Scholar 

  • Penn RD, Kroin JS, York MM, Cedarbaum JM (1997) Intrathecal ciliary neurotrophic factor delivery for treatment of amyotrophic lateral sclerosis (phase I trial). Neurosurgery 40: 94–99.

    PubMed  CAS  Google Scholar 

  • Perry TL, Hansen S, Jones K (1987) Brain glutamate deficiency in amyotrophic lateral sclerosis. Neurology 37: 1845–1848.

    PubMed  CAS  Google Scholar 

  • Plaitakis A, Constantakakis E, Smith J (1988) The neuroexcitotoxic amino acids glutamate and aspartate are altered in the spinal cord and brain in amyotrophic lateral sclerosis. Ann Neurol 24: 446–449.

    Article  PubMed  CAS  Google Scholar 

  • Riepe M, Hori N, Ludolph AC, Carpenter DO, Spencer PS, Allen CA (1992) Inhibition of energy metabolism by 3-nitropropionic acid activates ATP-sensitive potassium channels. Brain Res 586: 61–66.

    Article  PubMed  CAS  Google Scholar 

  • Riepe M, Ludolph A, Seelig M, Spencer PS, Ludolph AC (1994) Increase of ATP levels by glutamate antagonists is unrelated to neuroprotection. Neuroreport 5: 2130–2132.

    Article  PubMed  CAS  Google Scholar 

  • Riepe HW, Hori N, Ludolph AC, Carpenter DO (1995) Failure of neuronal ion exchange, not potentiated excitation causes excitotoxicity after inhibition of oxidative phosphorylation. Neuroscience 64: 91–97.

    Article  PubMed  CAS  Google Scholar 

  • Riviere M, Meininger V, Zeisser P, Munsat T (1998) An analysis of extended survival in patients with amyotrophic lateral sclerosis treated with riluzole. Arch Neurol 55:526–528.

    Article  PubMed  CAS  Google Scholar 

  • Rosen DR, Siddique T, Pattersson D, Figlewicz DA, Sapp P, Hentati A et al. (1993) Mutations in Cu/Zn Superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis. Nature 362: 59–62.

    Article  PubMed  CAS  Google Scholar 

  • Rothstein JD, Martin LJ, Kuncl RW (1992) Decreased brain and spinal cord glutamate transport in amyotrophic lateral sclerosis. N Engl J Med 326: 1464–1468.

    Article  PubMed  CAS  Google Scholar 

  • Rothstein JD, Van Kammen M, Levey AI, Martin L, Kuncl RW (1995) Selective loss of glial glutamate transporter GLT-1 in amyotrophic lateral sclerosis. Ann Neurol 38: 73–84.

    Article  PubMed  CAS  Google Scholar 

  • Sendtner M (1997) Gene therapy for motor neuron disease. Nat Med 3: 380–381.

    Article  PubMed  CAS  Google Scholar 

  • Shaw PJ, Forrest V, Ince PG, Richardson JP, Wastell HJ (1995) CSF and plasma amino acid levels in motor neuron disease: elevation of CSF glutamate in a subset of patients. Neurodegeneration 4: 209–216.

    Article  PubMed  CAS  Google Scholar 

  • Stefani A, Spadoni F, Bernardi G (1997) Differential inhibition by riluzole, lamotrigine, and phenytoin of sodium and calcium currents in cortical neurons: implications for neuroprotective strategies. Exp Neurol 147: 115–122.

    Article  PubMed  CAS  Google Scholar 

  • Taylor CP (1995) Gabapentin — mechanisms of action. In: Levy RH, Mattson RH, Meldrum BNM (eds) Antiepileptic drugs, 4th ed. Raven Press, New York, pp 829–841.

    Google Scholar 

  • Terro F, Lasort M, Vlader F, Ludolph A, Hugon J (1996) Antioxidant drugs block in vitro the neurotoxicity of CSF from patients with amyotrophic lateral sclerosis. Neuroreport 7: 1970–1972.

    Article  PubMed  CAS  Google Scholar 

  • Torp R, Lekieffre D, Levy LM, Haug FM, Danbolt NC, Meldrum BS, Ottersen OP (1995) Reduced postischemic expression of a glial glutamate transporter, GLT1, in the rat hippocampus. Exp Brain Res 103: 51–58.

    Article  PubMed  CAS  Google Scholar 

  • Tsai G, Stauch-Slusher B, Sim L et al. (1990) Reductions in acidic amino acids and N-acetyl-aspartyl-glutamate (NAAG) in amyotrophic lateral sclerosis CSF. Brain Res 556: 151–156.

    Article  Google Scholar 

  • Wiedemann FR, Winkler K, Kuznetsov AV, Bartels C, Vielhaber S, Feistner H, Kunz WS (1998) Impairment of mitochondrial function in skeletal muscle of patients with amyotrophic lateral sclerosis. J Neurol Sci 156: 65–72.

    Article  PubMed  CAS  Google Scholar 

  • Wong PC, Pardo CA, Borchelt DR, Lee MK, Copeland NG, Jenkins NA, Sisodia SS, Cleveland DW, Price DL (1995) An adverse property of a familial ALS-linked SOD1 mutation causes motor neuron disease characterized by vacuolar degeneration of mitochondria. Neuron 14: 1105–1116.

    Article  PubMed  CAS  Google Scholar 

  • World Federation of Neurology Research Group on Neuromuscular Diseases (1994) El Escorial World Federation of Neurology criteria for the diagnosis of amyotrophic lateral sclerosis. J Neurol Sci 124(Suppl.): 96–107.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Neurology, University of Ulm, Steinhövelstrasse 9, D-89075, Ulm, Federal Republic of Germany

    Dr. A. C. Ludolph, T. Meyer & M. W. Riepe

Authors
  1. Dr. A. C. Ludolph
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. T. Meyer
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. M. W. Riepe
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Universitätsklinik für Neurologie, Innsbruck, Österreich

    W. Poewe  & G. Ransmayr  & 

Rights and permissions

Reprints and permissions

Copyright information

© 1999 Springer-Verlag/Wien

About this paper

Cite this paper

Ludolph, A.C., Meyer, T., Riepe, M.W. (1999). Antiglutamate therapy of ALS — which is the next step?. In: Poewe, W., Ransmayr, G. (eds) Advances in Research on Neurodegeneration. 6th International Winter Conference on N eurodegeneration, vol 55. Springer, Vienna. https://doi.org/10.1007/978-3-7091-6369-6_8

Download citation

  • DOI: https://doi.org/10.1007/978-3-7091-6369-6_8

  • Publisher Name: Springer, Vienna

  • Print ISBN: 978-3-211-83261-5

  • Online ISBN: 978-3-7091-6369-6

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation